Partial Laryngectomy for pT4a Laryngeal Cancer: Outcomes and Limits in Selected Cases.

OPHL T4 laryngeal cancer laryngeal cancer laryngeal preservation partial laryngectomy radiotherapy

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
22 May 2023
Historique:
received: 27 03 2023
revised: 04 05 2023
accepted: 15 05 2023
medline: 22 6 2023
pubmed: 22 6 2023
entrez: 22 6 2023
Statut: epublish

Résumé

A large multi-institutional case series of laryngeal cancer (LC) T4a was carried out, including 134 cases treated with open partial horizontal laryngectomies (OPHL) +/- post-operative radiation therapy (PORT). The goal was to understand better whether OPHL can be included among the viable options in selected pT4a LC patients who refuse a standard approach, represented by total laryngectomy (TL) + PORT. All 134 patients underwent OPHL type I (supraglottic), II (supracricoid), or III (supratracheal), according to the European Laryngological Society Classification. Comparing clinical and pathological stages showed pT up-staging in 105 cases (78.4%) and pN up-staging in 19 patients (11.4%). Five-year data on overall survival, disease-specific survival, disease-free survival, freedom from laryngectomy, and laryngo-esophageal dysfunction-free survival (rate of patients surviving without a local recurrence or requiring total laryngectomy and without a feeding tube or a tracheostomy) were, respectively, 82.1%, 89.8%, 75.7%, 89.7%, and 78.3%. Overall, complications were observed in 22 cases (16.4%). Sequelae were observed in 28 patients (20.9%). No patients died during the postoperative period. This large series highlights the good onco-functional results of low-volume pT4a laryngeal tumors, with minimal or absent cartilage destruction, treated with OPHLs. The level of standardization of the indication for OPHL should allow consideration of OPHL as a valid therapeutic option in cases where the patient refuses total laryngectomy or non-surgical protocols with concomitant chemo-radiotherapy.

Identifiants

pubmed: 37345197
pii: cancers15102861
doi: 10.3390/cancers15102861
pmc: PMC10216219
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Laryngoscope. 2006 Oct;116(10):1907-17
pubmed: 17003702
Head Neck. 2017 Aug;39(8):1609-1620
pubmed: 28464542
J Natl Compr Canc Netw. 2014 Oct;12(10):1454-87
pubmed: 25313184
Head Neck. 2015 Apr;37(4):557-66
pubmed: 24677483
Acta Otorhinolaryngol Ital. 2015 Jun;35(3):146-56
pubmed: 26246658
Coll Antropol. 2012 Nov;36 Suppl 2:7-12
pubmed: 23397747
Cancer. 2015 May 15;121(10):1608-19
pubmed: 25586197
Ann Otol Rhinol Laryngol. 2006 Nov;115(11):827-32
pubmed: 17165665
Head Neck. 2016 Apr;38 Suppl 1:E649-57
pubmed: 25866908
Laryngoscope. 1990 Jul;100(7):735-41
pubmed: 2362533
Eur Arch Otorhinolaryngol. 2014 Sep;271(9):2489-96
pubmed: 24691854
Head Neck. 2021 Nov;43(11):3459-3467
pubmed: 34405480
Cancers (Basel). 2020 Aug 11;12(8):
pubmed: 32796540
Eur Arch Otorhinolaryngol. 2015 Nov;272(11):3463-8
pubmed: 25359194
Int Arch Otorhinolaryngol. 2021 Jul 19;26(1):e075-e084
pubmed: 35096162
Oncologist. 2010;15 Suppl 3:25-9
pubmed: 21036886
Acta Otorhinolaryngol Ital. 2016 Oct;36(5):403-407
pubmed: 27958601
Acta Otorhinolaryngol Ital. 2019 Aug;39(4):235-243
pubmed: 31501615
Head Neck. 2018 Sep;40(9):1897-1908
pubmed: 29756363
J Clin Oncol. 2006 Aug 1;24(22):3693-704
pubmed: 16832122
Arch Otolaryngol Head Neck Surg. 2005 Jul;131(7):620-5
pubmed: 16027286
Otolaryngol Clin North Am. 2015 Aug;48(4):565-84
pubmed: 26096138
J Clin Oncol. 2015 Oct 10;33(29):3262-8
pubmed: 26351339
Medicina (Kaunas). 2021 Mar 15;57(3):
pubmed: 33804150
Head Neck. 1998 Sep;20(6):504-9
pubmed: 9702536
Head Neck. 2016 Apr;38 Suppl 1:E333-40
pubmed: 25581514
Eur Arch Otorhinolaryngol. 2021 Oct;278(10):4059-4065
pubmed: 33599842
Head Neck. 2015 Oct;37(10):1417-24
pubmed: 24839082
Arch Otolaryngol Head Neck Surg. 2002 Jul;128(7):751-8
pubmed: 12117328
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
pubmed: 17237035
Acta Otolaryngol. 2006 Jun;126(6):640-9
pubmed: 16720450
Cancers (Basel). 2019 Mar 01;11(3):
pubmed: 30832209

Auteurs

Giovanni Succo (G)

Otorhinolaryngology Unit, San Giovanni Bosco Hospital, 10154 Turin, Italy.
Oncology Department, University of Turin, 10124 Torino, Italy.

Andy Bertolin (A)

Otorhinolaryngology Unit, Vittorio Veneto Hospital, AULSS2 Treviso, 31029 Vittorio Veneto, Italy.

Izabela Costa Santos (IC)

Brazilian National Cancer Institute, Rio de Janeiro 20230-130, RJ, Brazil.

Martina Tascone (M)

Otorhinolaryngology Unit, San Giovanni Bosco Hospital, 10154 Turin, Italy.

Marco Lionello (M)

Otorhinolaryngology Unit, Vittorio Veneto Hospital, AULSS2 Treviso, 31029 Vittorio Veneto, Italy.

Marco Fantini (M)

Otorhinolaryngology Unit, San Giovanni Bosco Hospital, 10154 Turin, Italy.

Andressa Silva de Freitas (AS)

Brazilian National Cancer Institute, Rio de Janeiro 20230-130, RJ, Brazil.

Ilaria Bertotto (I)

Radiology Service, Candiolo Cancer Institute FPO IRCCS, Candiolo, 10060 Turin, Italy.

Andrea Elio Sprio (AE)

Department of Research, ASOMI College of Sciences, 2080 Marsa, Malta.

Giuseppe Sanguineti (G)

Department of Radiation Oncology, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.

Fernando Luiz Dias (FL)

Brazilian National Cancer Institute, Rio de Janeiro 20230-130, RJ, Brazil.

Giuseppe Rizzotto (G)

Otorhinolaryngology Unit, Vittorio Veneto Hospital, AULSS2 Treviso, 31029 Vittorio Veneto, Italy.

Erika Crosetti (E)

Otorhinolaryngology Unit, San Giovanni Bosco Hospital, 10154 Turin, Italy.

Classifications MeSH